FILSPARI® (sparsentan) achieved a clinically meaningful difference vs. irbesartan in eGFR total slope (1.0 mL/min/1.73m2 per year) [p= 0.058] and eGFR chronic slope (1.1 mL/min/1.73m2 per year) [p=0.037]. Patients
Unity Software reported first-quarter GAAP losses of 75 cents per share, missing the analyst consensus estimate of losses of 65 cents per share. Quarterly sales clocked in at $460 million, beating the analyst consensus estimate of $431.55 million by 6.59%.